After a successful share issue during the summer, the board of Cline Scientific has carefully analyzed what the business should continue to focus on during the fall in order to reach the goals set for StemCART. The result of this analysis clearly shows a great need to continue the pre-clinical activities in order to build a stronger result base for a future partner. The person who is best suited to lead this work is Hanne Evenbratt because she has been leading for a long time and is well versed in that part of the business. Combining this work with the CEO task and efforts to create contacts with future partners then becomes completely unreasonable. Therefore, it is with pleasure that a unanimous board sees that Patrik Sundh now feels ready to shoulder the responsibility once again as CEO, effective immediately, so that the company's future and success can be secured.

"We have seriously considered the challenges the company is facing and have come to the conclusion that this is both the only and the best solution. The board has both continued full confidence and has great respect for Patrik and his long experience from Cline and in the Life Science area. We thank Hanne Evenbratt for having fulfilled the role of CEO meritoriously over the past few months and now welcome Patrik Sundh back to the post."

Johan Bjurquist, Chairman of the Board

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 10:14am CEST on 13 September 2023.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585088